Mesoblast’s Ryoncil Gains Permanent CMS J-Code for Billing and Reimbursement

Group 1 - Mesoblast Limited's product Ryoncil (remestemcel-L-rknd) received a permanent Healthcare Common Procedure Coding System (HCPCS) J-Code (J3402) from the US Medicare & Medicaid Services, effective October 1 [1][2] - The assignment of the J-Code is a significant commercial milestone, providing a standardized billing pathway that facilitates reimbursement by Medicare, Medicaid, and commercial payers, thus improving patient access to Ryoncil [2][3] - Ryoncil is the first mesenchymal stromal cell product approved by the US FDA for any indication and is specifically approved for pediatric patients aged 2 months and older with steroid-refractory acute graft-versus-host disease [3][4] Group 2 - Mesoblast develops allogeneic cellular medicines aimed at treating severe inflammatory conditions, utilizing a proprietary technology platform based on mesenchymal lineage cells [3][4] - The company operates in multiple regions, including Australia, the US, Singapore, and Switzerland, focusing on regenerative medicine products [4]